Exenatide added to insulin glargine-treated patients with type 2 diabetes provided excellent fasting and postprandial control with weight loss and no increased risk of hypoglycaemia

被引：0
|
作者：
Bergenstal, R. M. [1 ]
Buse, J. B. [2 ]
Glass, L. C. [3 ]
Heilmann, C. R. [3 ]
Lewis, M. S. [3 ]
Kwan, A. Y. M. [4 ]
Hoogwerf, B. J. [4 ]
Rosenstock, J. [5 ]
机构：
[1] Int Diabet Ctr, Minneapolis, MN USA
[2] UNC Sch Med, Chapel Hill, NC USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Lilly USA LLC, Indianapolis, IN USA
[5] Dallas Diabet & Endocrine Ctr, Dallas, TX USA
来源：
DIABETOLOGIA | 2010年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
73
引用
收藏
页码：S37 / S37
页数：1
相关论文
共 50 条
  • [1] Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
    Rosenstock, Julio
    Shenouda, Sylvia K.
    Bergenstal, Richard M.
    Buse, John B.
    Glass, Leonard C.
    Heilmann, Cory R.
    Kwan, Anita Y. M.
    MacConell, Leigh A.
    Hoogwerf, Byron James
    [J]. DIABETES CARE, 2012, 35 (05) : 955 - 958
  • [2] Exenatide achieved equivalent glycaemic control to insulin glargine, with weight reduction and less nocturnal hypoglycaemia, in metformin and sulfonylurea-treated type 2 diabetes
    Heine, RJ
    Van Gaal, LF
    Johns, D
    Mihm, MJ
    Widel, MH
    Brodows, RG
    [J]. DIABETOLOGIA, 2005, 48 : A3 - A3
  • [3] Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes
    Brodows, Robert G.
    Qu, Yongming
    Johns, Don
    Kim, Dennis
    Holcombe, John H.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (05) : 1395 - 1397
  • [4] Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin
    Dailey, G. E.
    Gao, L.
    Aurand, L.
    Garg, S. K.
    [J]. DIABETES OBESITY & METABOLISM, 2013, 15 (12): : 1085 - 1092
  • [5] Exenatide reduced body weight compared to insulin glargine in metformin and sulfonylurea-treated patients with type 2 diabetes
    Brodows, R
    Kim, D
    Burger, J
    Mihm, M
    Johns, D
    [J]. OBESITY RESEARCH, 2005, 13 : A132 - A132
  • [6] Dynamics of Weight Change and Glycemic Control in Patients with Type 2 Diabetes Treated with Exenatide or Insulin
    Paul, Sanjoy K.
    Best, Jennie H.
    Naughton, Margaret
    Maggs, David
    [J]. DIABETES, 2010, 59 : A181 - A181
  • [7] Duration of diabetes and hypoglycaemia rates in type 2 diabetes patients treated with insulin glargine vs NPH insulin
    Dailey, G.
    Aurand, L.
    Garg, S.
    [J]. DIABETOLOGIA, 2011, 54 : S262 - S262
  • [8] Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide
    Pujante Alarcon, Pedro
    Hellin Gil, Maria Dolores
    Miguel Roman, Luis
    Ferrer Gomez, Mercedes
    Garcia Zafra, Maria Victoria
    Tebar Masso, Javier
    [J]. MEDICINA CLINICA, 2012, 139 (13): : 572 - 578
  • [9] Once-Weekly Exenatide Used for 6 Months Provided Both Improved Glycemic Control and Weight Loss Compared to Sitagliptin, Pioglitazone, or Insulin Glargine in Metformin-Treated Patients with Type 2 Diabetes
    Horton, Edward
    Taylor, Kristin
    Porter, T. K. Booker
    Han, Jenny
    Wilhelm, Ken
    Harris, Carmen
    [J]. DIABETES, 2010, 59 : A163 - A163
  • [10] Improved treatment satisfaction in patients with type-2 diabetes treated with exenatide or insulin glargine
    Secnik, K
    Hayes, C
    Matza, L
    Kim, S
    Oglesby, A
    Yurgin, N
    Brodows, R
    Malley, K
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A155 - A156
12345